| First Author | Crow AR | Year | 2011 |
| Journal | Blood | Volume | 117 |
| Issue | 3 | Pages | 971-4 |
| PubMed ID | 21045192 | Mgi Jnum | J:168394 |
| Mgi Id | MGI:4888156 | Doi | 10.1182/blood-2010-05-280115 |
| Citation | Crow AR, et al. (2011) Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?. Blood 117(3):971-4 |
| abstractText | To explore the potential for monoclonal antibodies as a treatment for immune thrombocytopenia (ITP) and to further explore their mechanisms of action, we tested 8 monoclonal CD44 antibodies in murine ITP and found 4 antibodies that could successfully ameliorate ITP; 2 of these antibodies function at a full 3-log fold lower dosage compared with IVIg. Further characterization of the 2 most successful antibodies (5035-41.1D and KM114) demonstrated that, similar to IVIg: (1) the presence of the inhibitory IgG receptor FcgammaRIIB was required for their ameliorative function, (2) complement-deficient mice responded to anti-CD44 treatment, and (3) human transgenic FcgammaRIIA-expressing mice also responded to the CD44 therapeutic modality. Dissimilar to IVIg, the Fc portion of the CD44 antibody was not required. These data demonstrate that CD44 antibodies can function therapeutically in murine ITP and that they could potentially provide a very-low-dose recombinant therapy for the amelioration of human ITP. |
